keyword
https://read.qxmd.com/read/38643811/prolonged-delivery-of-hiv-1-vaccine-nanoparticles-from-hydrogels
#21
JOURNAL ARTICLE
Raphael Mietzner, Clara Barbey, Heike Lehr, Christian E Ziegler, David Peterhoff, Ralf Wagner, Achim Goepferich, Miriam Breunig
Immunization is a straightforward concept but remains for some pathogens like HIV-1 a challenge. Thus, new approaches towards increasing the efficacy of vaccines are required to turn the tide. There is increasing evidence that antigen exposure over several days to weeks induces a much stronger and more sustained immune response compared to traditional bolus injection, which usually leads to antigen elimination from the body within a couple of days. Therefore, we developed a poly(ethylene) glycol (PEG) hydrogel platform to investigate the principal feasibility of a sustained release of antigens to mimic natural infection kinetics...
April 19, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38643540/a-rational-designed-multi-epitope-vaccine-elicited-robust-protective-efficacy-against-klebsiella-pneumoniae-lung-infection
#22
JOURNAL ARTICLE
Jingwen Liao, Xiaoli Zhang, Xi Zeng, Zhuo Zhao, Tianjun Sun, Zhenping Xia, Haiming Jing, Yue Yuan, Zhifu Chen, Qiang Gou, Liqun Zhao, Weijun Zhang, Quanming Zou, Jinyong Zhang
BACKGROUND: The emergence of drug-resistant strains of Klebsiella pneumoniae (K. pneumoniae) has become a significant challenge in the field of infectious diseases, posing an urgent need for the development of highly protective vaccines against this pathogen. METHODS AND RESULTS: In this study, we identified three immunogenic extracellular loops based on the structure of five candidate antigens using sera from K. pneumoniae infected mice. The sequences of these loops were linked to the C-terminal of an alpha-hemolysin mutant (mHla) from Staphylococcus aureus to generate a heptamer, termed mHla-EpiVac...
April 20, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38641838/ageing-of-plasmodium-falciparum-malaria-sporozoites-alters-their-motility-infectivity-and-reduces-immune-activation-in-vitro
#23
JOURNAL ARTICLE
Roos van Schuijlenburg, Samaneh Azargoshasb, Clarize M de Korne, Jeroen C Sijtsma, Sascha Bezemer, Alwin J van der Ham, Els Baalbergen, Fiona Geurten, Laura M de Bes-Roeleveld, Severine C Chevalley-Maurel, Matthias N van Oosterom, Fijs W B van Leeuwen, Blandine Franke-Fayard, Meta Roestenberg
BACKGROUND: Sporozoites (SPZ), the infective form of Plasmodium falciparum malaria, can be inoculated into the human host skin by Anopheline mosquitoes. These SPZ migrate at approximately 1 µm/s to find a blood vessel and travel to the liver where they infect hepatocytes and multiply. In the skin they are still low in number (50-100 SPZ) and vulnerable to immune attack by antibodies and skin macrophages. This is why whole SPZ and SPZ proteins are used as the basis for most malaria vaccines currently deployed and undergoing late clinical testing...
April 19, 2024: Malaria Journal
https://read.qxmd.com/read/38641791/immunogenicity-and-safety-of-a-recombinant-covid-19-vaccine-zf2001-as-heterologous-booster-after-priming-with-inactivated-vaccine-in-healthy-children-and-adolescents-aged-3-17-years-an-open-labeled-single-arm-clinical-trial
#24
JOURNAL ARTICLE
Tao Huang, Qianqian Hu, Xiang Zhou, Huaiyu Yang, Wei Xia, Feng Cao, Minglu Deng, Xiaoxue Teng, Fan Ding, Zaixin Zhong, Lidong Gao, Jiufeng Sun, Lihui Gong
Considering that neutralizing antibody levels induced by two doses of the inactivated vaccine decreased over time and had fallen to low levels by 6 months, and homologous and heterologous booster immunization programs have been implemented in adults in China. The booster immunization of recombinant COVID-19 vaccine (ZF2001) after priming with inactivated vaccine in healthy children and adolescents has not been reported. We performed an open-labeled, single-arm clinical trial to evaluate the safety and immunogenicity of heterologous booster immunization with ZF2001 after priming with inactivated vaccine among 240 population aged 3-17 years in China...
April 19, 2024: BMC Infectious Diseases
https://read.qxmd.com/read/38641498/immunogenicity-and-protective-efficacy-of-a-multivalent-herpesvirus-vectored-vaccine-against-h9n2-low-pathogenic-avian-influenza-in-chicken
#25
JOURNAL ARTICLE
Fiona Ingrao, Eva Ngabirano, Fabienne Rauw, Gwenaëlle Dauphin, Bénédicte Lambrecht
The application of recombinant herpesvirus of turkey, expressing the H9 hemagglutinin gene from low pathogenic avian influenza virus (LPAIV) H9N2 and the avian orthoavulavirus-1 (AOAV-1) (commonly known as Newcastle Disease virus (NDV)) fusion protein (F) as an rHVT-H9-F vaccine, is an alternative to currently used classical vaccines. This study investigated H9- and ND-specific humoral and mucosal responses, H9-specific cell-mediated immunity, and protection conferred by the rHVT-H9-F vaccine in specific pathogen-free (SPF) chickens...
April 18, 2024: Vaccine
https://read.qxmd.com/read/38641492/vlps-generated-by-the-fusion-of-rsv-f-or-hmpv-f-glycoprotein-to-hiv-gag-show-improved-immunogenicity-and-neutralizing-response-in-mice
#26
JOURNAL ARTICLE
Benjamin Trinité, Eberhard Durr, Anna Pons-Grífols, Gregory O'Donnell, Carmen Aguilar-Gurrieri, Silveria Rodriguez, Victor Urrea, Ferran Tarrés, Joel Mane, Raquel Ortiz, Carla Rovirosa, Jorge Carrillo, Bonaventura Clotet, Lan Zhang, Julià Blanco
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccines have been long overdue. Structure-based vaccine design created a new momentum in the last decade, and the first RSV vaccines have finally been approved in older adults and pregnant individuals. These vaccines are based on recombinant stabilized pre-fusion F glycoproteins administered as soluble proteins. Multimeric antigenic display could markedly improve immunogenicity and should be evaluated in the next generations of vaccines. Here we tested a new virus like particles-based vaccine platform which utilizes the direct fusion of an immunogen of interest to the structural human immunodeficient virus (HIV) protein Gag to increase its surface density and immunogenicity...
April 18, 2024: Vaccine
https://read.qxmd.com/read/38640639/orf-virus-as-an-adjuvant-enhances-the-immune-response-to-a-pcv2-subunit-vaccine
#27
JOURNAL ARTICLE
Jie Sun, Jun Ma, Longfei Chen, Shaobo Xiao, Xun Xiao, Liurong Fang
Orf virus (ORFV), a member of the genus Parapoxvirus, possesses an excellent immune activation capability, which makes it a promising immunomodulation agent. In this study, we evaluated ORFV as a novel adjuvant to enhance the immune response of mice to a subunit vaccine using porcine circovirus type 2 (PCV2) capsid (Cap) protein as a model. Our results showed that both inactivated and live attenuated ORFV activated mouse bone marrow-derived dendritic cells and increased expression of immune-related cytokines interleukin (IL)-1β, IL-6, and TNF-α...
April 16, 2024: Veterinary Microbiology
https://read.qxmd.com/read/38640558/immune-responses-induced-by-mycobacterium-tuberculosis-heat-resistant-antigen-mtb-hag-upon-co-administration-with-bacillus-calmette-gu%C3%A3-rin-in-mice
#28
JOURNAL ARTICLE
Fangzheng Guo, Jing Wei, Yamin Song, Jianhan Song, Ying Wang, Kangsheng Li, Baiqing Li, Zhongqing Qian, Xiaojing Wang, Hongtao Wang, Tao Xu
OBJECTIVES: To preliminarily assess the immunogenicity of Mtb-HAg in mice and the synergistic effect provided by HAg when co-immunised with BCG. METHODS: Mice were randomly grouped for different immunisations and then spleens were aseptically removed and lymphocytes were extracted for immediate detection of cytokines transcript levels and stimulation index(SI), cytokine secretion and multifunctional antigen-specific T cells were detected after incubation for different times...
April 17, 2024: Cytokine
https://read.qxmd.com/read/38640442/single-cell-oral-delivery-platform-for-enhanced-acid-resistance-and-intestinal-adhesion
#29
JOURNAL ARTICLE
Guangmin Wei, Moon Tay Yue Feng, Zhangyong Si, Mary B Chan-Park
Oral delivery of cells, such as probiotics and vaccines, has proved to be inefficient since cells are generally damaged in an acidic stomach prior to arrival at the intestine to exert their health benefits. In addition, short retention in the intestine is another obstacle which affects inefficiency. To overcome these obstacles, a cell-in-shell structure was designed with pH-responsive and mucoadhesive properties. The pH-responsive shell consisting of three cationic layers of chitosan and three anionic layers of trans -cinnamic acid ( t -CA) was made via layer-by-layer (LbL) assembly...
April 19, 2024: ACS Applied Materials & Interfaces
https://read.qxmd.com/read/38639919/integrating-multisector-molecular-characterization-into-personalized-peptide-vaccine-design-for-patients-with-newly-diagnosed-glioblastoma
#30
JOURNAL ARTICLE
Tanner M Johanns, Elizabeth A R Garfinkle, Katherine E Miller, Alexandra J Livingstone, Kaleigh F Roberts, Lakshmi Prakruthi Rao Venkata, Joshua L Dowling, Michael R Chicoine, Ralph G Dacey, Gregory J Zipfel, Albert H Kim, Elaine R Mardis, Gavin P Dunn
PURPOSE: Glioblastoma (GBM) patient outcomes remain poor despite multimodality treatment with surgery, radiation, and chemotherapy. There are few immunotherapy options due to the lack of tumor immunogenicity. Several clinical trials have reported promising results with cancer vaccines. To date, studies have used data from a single tumor site to identify targetable antigens, but this approach limits the antigen pool and is antithetical to the heterogeneity of GBM. We have implemented multisector sequencing to increase the pool of neoantigens across the GBM genomic landscape that can be incorporated into personalized peptide vaccines called NeoVax...
April 19, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38637990/bis-2-f-cg-s-a-s-mp-isomers-encapsulated-in-cytidinyl-cationic-lipids-act-as-potent-in-situ-autologous-tumor-vaccines
#31
JOURNAL ARTICLE
Jing Yu, Xiaotong Yu, Xudong Sun, Quanxin Wang, Sijie Long, Runan Ren, Zhu Guan, Zhenjun Yang
Cancer immunotherapy has greatly improved the prognosis of tumor-bearing patients. Nevertheless, cancer patients exhibit low response rates to current immunotherapy drugs, such as PD1 and PDL1 antibodies. Cyclic dinucleotide analogs are a promising class of immunotherapeutic agents. In this study, in situ autologous tumor vaccines, composed of Bis-2'-F-cGS AS MP phosphonothioate isomers (FGA-di-pS-2 or FGA-di-pS-4) and cytidinyl/cationic lipids (Mix), were constructed. Intravenous (i.v.) and intratumoral (i...
April 17, 2024: Molecular Therapy
https://read.qxmd.com/read/38637841/new-recommendations-on-cerebral-venous-and-dural-sinus-thrombosis-from-the-german-consensus-based-s2k-guideline
#32
JOURNAL ARTICLE
C Weimar, J Beyer-Westendorf, F O Bohmann, G Hahn, S Halimeh, S Holzhauer, C Kalka, M Knoflach, H-C Koennecke, F Masuhr, M-L Mono, U Nowak-Göttl, E Scherret, M Schlamann, B Linnemann
Over the last years, new evidence has accumulated on multiple aspects of diagnosis and management of cerebral venous and dural sinus thrombosis (CVT) including identification of new risk factors, studies on interventional treatment as well as treatment with direct oral anticoagulants. Based on the GRADE questions of the European Stroke Organization guideline on this topic, the new German guideline on CVT is a consensus between expert representatives of Austria, Germany and Switzerland. New recommendations include:• CVT occurring in the first weeks after SARS-CoV-2 vaccination with vector vaccines may be associated with severe thrombocytopenia, indicating the presence of a prothrombotic immunogenic cause (Vaccine-induced immune thrombotic thrombocytopenia; VITT)...
April 19, 2024: Neurological research and practice
https://read.qxmd.com/read/38637722/diet-switch-pre-vaccination-improves-immune-response-and-metabolic-status-in-formerly-obese-mice
#33
JOURNAL ARTICLE
Rebekah Honce, Ana Vazquez-Pagan, Brandi Livingston, Alexandra H Mandarano, Benjamin A Wilander, Sean Cherry, Virginia Hargest, Bridgett Sharp, Pamela H Brigleb, Ericka Kirkpatrick Roubidoux, Lee-Ann Van de Velde, R Chris Skinner, Maureen A McGargill, Paul G Thomas, Stacey Schultz-Cherry
Metabolic disease is epidemiologically linked to severe complications upon influenza virus infection, thus vaccination is a priority in this high-risk population. Yet, vaccine responses are less effective in these same hosts. Here we examined how the timing of diet switching from a high-fat diet to a control diet affected influenza vaccine efficacy in diet-induced obese mice. Our results demonstrate that the systemic meta-inflammation generated by high-fat diet exposure limited T cell maturation to the memory compartment at the time of vaccination, impacting the recall of effector memory T cells upon viral challenge...
April 18, 2024: Nature Microbiology
https://read.qxmd.com/read/38637636/an-omicron-specific-self-amplifying-mrna-booster-vaccine-for-covid-19-a-phase-2-3-randomized-trial
#34
JOURNAL ARTICLE
Amit Saraf, Rohan Gurjar, Swarnendu Kaviraj, Aishwarya Kulkarni, Durgesh Kumar, Ruta Kulkarni, Rashmi Virkar, Jayashri Krishnan, Anjali Yadav, Ekta Baranwal, Ajay Singh, Arjun Raghuwanshi, Praveen Agarwal, Laxman Savergave, Sanjay Singh
Here we conducted a multicenter open-label, randomized phase 2 and 3 study to assess the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron-specific (BA.1/B.1.1.529), monovalent, thermostable, self-amplifying mRNA vaccine, GEMCOVAC-OM, when administered intradermally as a booster in healthy adults who had received two doses of BBV152 or ChAdOx1 nCoV-19. GEMCOVAC-OM was well tolerated with no related serious adverse events in both phase 2 and phase 3. In phase 2, the safety and immunogenicity of GEMCOVAC-OM was compared with our prototype mRNA vaccine GEMCOVAC-19 (D614G variant-specific) in 140 participants...
April 18, 2024: Nature Medicine
https://read.qxmd.com/read/38637586/immune-response-stability-to-the-sars-cov-2-mrna-vaccine-booster-is-influenced-by-differential-splicing-of-hla-genes
#35
JOURNAL ARTICLE
Cíntia Barros Santos-Rebouças, Cristina Dos Santos Ferreira, Jeane de Souza Nogueira, Otávio José Brustolini, Luiz Gonzaga Paula de Almeida, Alexandra Lehmkuhl Gerber, Ana Paula de Campos Guimarães, Rafael Mina Piergiorge, Cláudio José Struchiner, Luís Cristóvão Porto, Ana Tereza Ribeiro de Vasconcelos
Many molecular mechanisms that lead to the host antibody response to COVID-19 vaccines remain largely unknown. In this study, we used serum antibody detection combined with whole blood RNA-based transcriptome analysis to investigate variability in vaccine response in healthy recipients of a booster (third) dose schedule of the mRNA BNT162b2 vaccine against COVID-19. The cohort was divided into two groups: (1) low-stable individuals, with antibody concentration anti-SARS-CoV IgG S1 below 0.4 percentile at 180 days after boosting vaccination; and (2) high-stable individuals, with antibody values greater than 0...
April 18, 2024: Scientific Reports
https://read.qxmd.com/read/38637521/sars-cov-2-booster-vaccine-dose-significantly-extends-humoral-immune-response-half-life-beyond-the-primary-series
#36
JOURNAL ARTICLE
Chapin S Korosec, David W Dick, Iain R Moyles, James Watmough
SARS-CoV-2 lipid nanoparticle mRNA vaccines continue to be administered as the predominant prophylactic measure to reduce COVID-19 disease pathogenesis. Quantifying the kinetics of the secondary immune response from subsequent doses beyond the primary series and understanding how dose-dependent immune waning kinetics vary as a function of age, sex, and various comorbidities remains an important question. We study anti-spike IgG waning kinetics in 152 individuals who received an mRNA-based primary series (first two doses) and a subset of 137 individuals who then received an mRNA-based booster dose...
April 18, 2024: Scientific Reports
https://read.qxmd.com/read/38637317/correction-to-interim-report-of-the-reactogenicity-and-immunogenicity-of-severe-acute-respiratory-syndrome-coronavirus-2-xbb-containing-vaccines
#37
(no author information available yet)
No abstract text is available yet for this article.
April 18, 2024: Journal of Infectious Diseases
https://read.qxmd.com/read/38637211/immunogenicity-and-safety-of-a-14-valent-pneumococcal-polysaccharide-conjugate-vaccine-pneubevax-14%C3%A2-administered-to-6-8%C3%A2-weeks-old-healthy-indian-infants-a-single-blind-randomized-active-controlled-phase-iii-study
#38
JOURNAL ARTICLE
Ramesh V Matur, Subhash Thuluva, Subbareddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Kamal Thammireddy, Piyush Paliwal, Niranjana S Mahantshetty, Mandyam Dhati Ravi, S Prashanth, Savita Verma, Jai Prakash Narayan
BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) reduced the number of cases of pneumococcal disease (PD). However, there is an increase in clinical and economic burden of PD from serotypes that are not part of the existing pneumococcal vaccines, particularly impacting pediatric and elder population. In addition, the regions where the PCV is not available, the disease burden remains high. In this study, immunogenicity and safety of the BE's 14-valent PCV (PNEUBEVAX 14™; BE-PCV-14) containing two additional epidemiologically important serotypes (22F and 33F) was evaluated in infants in comparison to licensed vaccine, Prevenar-13 (PCV-13)...
April 17, 2024: Vaccine
https://read.qxmd.com/read/38636739/recombinant-lactococcal-based-oral-vaccine-for-protection-against-streptococcus-agalactiae-infections-in-tilapia-oreochromis-niloticus
#39
JOURNAL ARTICLE
Kuan-Yee Wong, Megat Hamzah Megat Mazhar Khair, Adelene Ai-Lian Song, Mas Jaffri Masarudin, Jiun-Yan Loh, Chou-Min Chong, John Beardall, Michelle Yee-Mun Teo, Lionel Lian-Aun In
Streptococcosis outbreaks caused by Streptococcus agalactiae infection in tilapia aquaculture have been consistently reported and associated with high mortality and morbidity leading to significant economic losses. Existing vaccine candidates against Streptococcus spp. are designed for intraperitoneal injections that are not practical and labor-intensive which have prompted farmers to protect aquatic animals with antibiotics, thus encouraging the emergence of multidrug resistant bacteria. In this study, a live recombinant L...
April 16, 2024: Fish & Shellfish Immunology
https://read.qxmd.com/read/38633263/boosting-the-immunogenicity-of-the-coronavac-sars-cov-2-inactivated-vaccine-with-huoxiang-suling-shuanghua-decoction-a-randomized-double-blind-placebo-controlled-study
#40
RANDOMIZED CONTROLLED TRIAL
Ruying Tang, Linyuan Wang, Jianjun Zhang, Wenting Fei, Rui Zhang, Jinlian Liu, Meiyu Lv, Mengyao Wang, Ruilin Lv, Haipeng Nan, Ran Tao, Yawen Chen, Yan Chen, Yanxin Jiang, Hui Zhang
INTRODUCTION: In light of the public health burden of the COVID-19 pandemic, boosting the safety and immunogenicity of COVID-19 vaccines is of great concern. Numerous Traditional Chinese medicine (TCM) preparations have shown to beneficially modulate immunity. Based on pilot experiments in mice that showed that supplementation with Huoxiang Suling Shuanghua Decoction (HSSD) significantly enhances serum anti-RBD IgG titers after inoculation with recombinant SARS-CoV-2 S-RBD protein, we conducted this randomized, double-blind, placebo-controlled clinical trial aimed to evaluate the potential immunogenicity boosting effect of oral HSSD after a third homologous immunization with Sinovac's CoronaVac SARS-CoV-2 (CVS) inactivated vaccine...
2024: Frontiers in Immunology
keyword
keyword
99930
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.